01749nas a2200505   4500000000100000000000100001008004100002653001700043653001400060653001100074653001100085653001700096653001900113653002600132653001500158653001800173653001100191653001000202653002200212653002200234653002600256653001400282653000800296653001400304653002000318653001100338653001100349653001200360653002100372653001500393653001600408653001100424100002200435700001600457700001600473700001500489700002100504700002200525245006000547856014900607300001200756490000600768520044900774022002001223                                       d10aMaria Sabina10aPsilocybe10aReview10aWasson10aBiodiversity10abioprospecting10acultural anthropology10adepression10adrug industry10aethics10ahuman10aIndigenous people10aindigenous rights10aIntellectual property10aKnowledge10aLaw10alifestyle10amagic mushrooms10amarket10apatent10apatents10apriority journal10apsilocybin10apsilocybine10aritual1 aKonstantin Gerber1 aInti Flores1 aAngela Ruiz1 aIsmail Ali1 aNatalie Ginsberg1 aEduardo Schenberg00aEthical Concerns about Psilocybin Intellectual Property  uhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85100187437&doi=10.1021%2facsptsci.0c00171&partnerID=40&md5=bd61da077bb6c442d705e4431b9b6047  a573-5770 v43 aSince a 1957 exposé in Life Magazine, chemical compounds derived from Psilocybe mushrooms have been the focus of dozens of attempted and successful patents, most recently to treat depression. Regrettably, the Mazatec indigenous communities who stewarded these traditional medicines for millenia are not party to any of these patents, despite a number of international treaties asserting indigenous rights to their intangible cultural heritage.  a25759108 (ISSN)